Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug
Glenmark Pharmaceuticals shares surged more than 35 per cent to a new 52-week high on Monday, after the company said it had received an approval from the government's drug regulator to market and manufacture oral antiviral drug Favipiravir for treating mild to moderate COVID-19 patients in the country. On the BSE, Glenmark Pharma shares soared to as high as Rs 572.70 in the first half of the session, compared to their previous close of Rs 409.10.
The Mumbai-based drug maker said the clearance by the drug regulator was part of the government's Accelerated Approval Process, which takes into account the disease severity, rarity, and the availability or lack of alternative treatment. Glenmark said the drug would be for "restricted emergency use" in the country.
A generic version of Favipiravir will be manufactured and marketed by Glenmark under the name Fabiflu, and will be available in the strength of 200 milligrams. Glenmark has priced the strip of 34 tablets at Rs 3,500, costing around Rs 103 per tablet, the company said in a regulatory filing.
Use of Favipiravir has been approved by medical authorities in China, Japan, Canada and Saudi Arabia among other countries.
India has over 4.25 lakh coronavirus cases, recording the biggest single-day jump of 445 deaths amid renewed concerns over the rapid rise in new infections in the country. The spike in cases has taken the country's tally to 4,25,282 while the death count rose to 13,699, according to the Union Health Ministry data till Monday morning.
The coronavirus cases in Delhi have increased to 59,746. All coronavirus patients in Delhi will have to go to COVID-19 care centres and those who have facilities at home and have no co-morbidity can avail home isolation in the capital, the Centre said, hours after the Delhi government issued a revised order on home quarantine.
At 11:35 am, Glenmark shares traded 38.11 per cent higher at Rs 565.00 on the BSE, outperforming the benchmark Sensex index which was up 0.40 per cent.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.